Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide-Reference-Cited by-同舟云学术

Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide

Published:2008-03 Issue:3 Volume:29 Page:283-290
ISSN:0143-3636
Container-title:Nuclear Medicine Communications
language:en
Short-container-title:

Author:

Barone Raffaella,Walrand Stéphan,Konijnenberg Mark,Valkema Roelf,Kvols Larry K.,Krenning Eric P.,Pauwels Stanislas,Jamar François

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Radiology Nuclear Medicine and imaging,General Medicine

Reference36 articles.

1. Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo;Akizawa;Bioconjug Chem,1998

2. Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue;Hammond;Br J Cancer,1993

3. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo;de Jong;J Nucl Med,1996

4. 86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487) – A phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion;Jamar;Eur J Nucl Med Mol Imaging,2003

5. Radiation Protection. Nonstochastic Effects of Ionizing Radiation,1991

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Radionuclide Therapies for Patients with Neuro-endocrine Tumors;Current Oncology Reports;2024-04-10

2. Radionuclides for Targeted Therapy: Physical Properties;Molecules;2022-08-25

3. A novel theranostic probe [¹¹¹In]In-DO3A-NHS-nimotuzumab in glioma xenograft;Radiochimica Acta;2022-04-05

4. Renal and Red Marrow Dosimetry in Peptide Receptor Radionuclide Therapy: 20 Years of History and Ahead;International Journal of Molecular Sciences;2021-08-03

5. Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer;ChemMedChem;2021-05-10